Atopic dermatitis: A review of topical treatment options

Current Medical Research and Opinion

Volumn 26, Issue 3, 2010, Pages 633-640

  Simpson, Eric L ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Atopic dermatitis; Pimecrolimus cream; Tacrolimus ointment; Topical barrier cream; Topical corticosteroids

Indexed keywords

ALCLOMETASONE DIPROPIONATE; ATOPICLAIR; BETAMETHASONE DIPROPIONATE; BETAMETHASONE VALERATE; CALCINEURIN INHIBITOR; CERAMIDE; CERAVE; CETAPHIL; CLOBETASOL PROPIONATE; CORTICOSTEROID; DESOXIMETASONE; EMOLLIENT AGENT; EPICERAM; FLUOCINONIDE; FLUTICASONE PROPIONATE; GLYCEROL; HYDROCORTISONE BUTYRATE; HYDROCORTISONE VALERATE; LACTIC ACID; MIMYX; MOMETASONE FUROATE; NICOTINAMIDE; PETROLATUM; PIMECROLIMUS; PLASTIBASE; TACROLIMUS; TRIAMCINOLONE DIACETATE; ULOBETASOL PROPIONATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; UREA;

ACNE; ADRENAL CORTEX INSUFFICIENCY; ADRENAL SUPPRESSION; APPLICATION SITE BURNING; APPLICATION SITE PRURITUS; ATOPIC DERMATITIS; AVOIDANCE BEHAVIOR; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DRUG CHOICE; DRUG INDICATION; GROWTH RETARDATION; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; OUTCOME ASSESSMENT; PATIENT EDUCATION; PETECHIA; ROSACEA; SHORT SURVEY; SIDE EFFECT; SKIN ATROPHY; STRIA; TELANGIECTASIA;

ADMINISTRATION, CUTANEOUS; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHILD; CHILD, PRESCHOOL; DERMATITIS, ATOPIC; FEMALE; HUMANS; MALE;

EID: 76949097932     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903512156     Document Type: Short Survey

References (47)

1. Brown S, Reynolds NJ. Atopic and non-atopic eczema. BMJ 2006;332:584-588
2. Wü thrich B. Clinical aspects, epidemiology, and prognosis of atopic dermatitis. Ann Allergy Asthma Immunol 1999;83:464-470
3. Williams H, Robertson C, Stewart A, et al. Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood. J Allergy Clin Immunol 1999;103:125-138
4. Uehara M, Kimura C. Descendant family history of atopic dermatitis. Acta Derm Venereol 1993;73:62-63
5. Spergel JM, Paller AS. Atopic dermatitis and the atopic march. J Allergy Clin Immunol 2003;112:S118-27
6. Bender BG, Ballard R, Canono B, et al. Disease severity, scratching, and sleep quality in patients with atopic dermatitis. J Am Acad Dermatol 2008; 58:415-420
7. Leyden JJ, Marples RR, Kligman AM. Staphylococcus aureus in the lesions of atopic dermatitis. Br J Dermatol 1974;90:525-530
8. Hanifin JM, Rajka G. Diagnostic features of atopic eczema. Acta Derm Venereol (Stockh) 1980;92:44-47
9. Eichenfield LF, Hanifin JM, Luger TA, et al. Consensus conference on pedi-atric atopic dermatitis. J Am Acad Dermatol 2003;49:1088-1095
10. Lodén M. Barrier recovery and influence of irritant stimuli in skin treated with a moisturizing cream. Contact Dermatitis 1997;36:256-260
11. Loden M. The skin barrier and use of moisturizers in atopic dermatitis. Clin Dermatol 2003;21:145-157
12. Lucky AW, Leach AD, Laskarzewski P, et al. Use of an emollient as a steroid-sparing agent in the treatment of mild to moderate atopic dermatitis in children. Pediatr Dermatol 1997;14:321-324
13. Szczepanowska J, Reich A, Szepietowski JC. Emollients improve treatment results with topical corticosteroids in childhood atopic dermatitis: a randomized comparative study. Pediatr Allergy Immunol 2008;19:614-618
14. Di Nardo A, Wertz P, Giannetti A, et al. Ceramide and cholesterol composition of the skin of patients with atopic dermatitis. Acta Derm Venereol 1998; 78:27-30
15. Loden M, Andersson AC, Lindberg M. Improvement in skin barrier function in patients with atopic dermatitis after treatment with a moisturizing cream (Canoderm). Br J Dermatol 1999;140:264-267
16. Loden M, Andersson AC, Andersson C, et al. Instrumental and dermatologist evaluation of the effect of glycerine and urea on dry skin in atopic dermatitis. Skin Res Technol 2001;7:209-213
17. Soma Y, Kashima M, Imaizumi A, et al. Moisturizing effects of topical nico-tinamide on atopic dry skin. Int J Dermatol 2005;44:197-202
18. Loden M, Andersson AC, Anderson C, et al. A double-blind study comparing the effect of glycerin and urea on dry, eczematous skin in atopic patients. Acta Derm Venereol 2002;82:45-47
19. Chamlin SL, Kao J, Frieden IJ, et al. Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: changes in barrier function provide a sensitive indicator of disease activity. J Am Acad Dermatol 2002;47:198-208
20. Loden M, Barany E. Skin-identical lipids versus petrolatum in the treatment of tape-stripped and detergent-perturbed human skin. Acta Derm Venereol 2000;80:412-415
21. Simpson E, Brown P, Berry T, et al. A pilot study of emollient therapy for the primary prevention of atopic dermatitis. International Symposium of Atopic Dermatitis, Kyoto, Japan, 2008
22. Hanifin JM, Cooper KD, Ho VC, et al. Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association 'Administrative Regulations for Evidence-Based Clinical Practice Guidelines'. J Am Acad Dermatol 2004; 50:391-404
23. Akers WA. Risks of unoccluded topical steroids in clinical trials. Arch Dermatol 1980;116:786-788
24. Patel L, Clayton PE, Addison GM, et al. Adrenal function following topical steroid treatment in children with atopic dermatitis. Br J Dermatol 1995; 132:950-955
25. Callen J, Chamlin S, Eichenfield LF, et al. A systematic review of the safety of topical therapies for atopic dermatitis. Br J Dermatol 2007;156:203-221
26. Berth-Jones J, Damstra RJ, Golsch S, et al. Twice weekly fluticasone propio-nate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. BMJ 2003; 326:1367
27. Munzenberger PJ, Montejo JM. Safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Pharmacotherapy 2007;27:1020-1028
28. Kang S, Lucky AW, Pariser D, et al. Long-term safety and efficacy of tacro-limus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol 2001;44:S58-64
29. Protopic Prescribing Information. Astellas Pharma US, Inc. 2006. Available at: http://www.astellas.us/docs/protopic.pdf [Last accessed 18 December 2008]
30. Elidel Prescribing Information. Novartis Pharmaceuticals Corp., 2006. Available at: http://www.pharma.us.novartis.com/product/pi/pdf/elidel.pdf [Last accessed 18 December]
31. Hanifin JM, Paller AS, Eichenfield L, et al. Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis. J Am Acad Dermatol 2005;53:S186-94
32. Paller AS, Lebwohl M, Fleischer Jr AB, et al. Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies. J Am Acad Dermatol 2005;52:810-822
33. Breneman D, Fleischer Jr AB, Abramovits W, et al. Intermittent therapy for flare prevention and long-term disease control in stabilized atopic dermatitis: a randomized comparison of 3-times-weekly applications of tacrolimus ointment versus vehicle. J Am Acad Dermatol 2008;58:990-999
34. Gollnick H, Kaufmann R, Stough D, et al. Pimecrolimus cream 1% in the long-term management of adult atopic dermatitis: prevention of flare progression. A randomized controlled trial. Br J Dermatol 2008;158:1083-1093
35. Draelos ZD. Use of topical corticosteroids and topical calcineurin inhibitors for the treatment of atopic dermatitis in thin and sensitive skin areas. Curr Med Res Opin 2008;24:985-994
36. Abramovits W, Boguniewicz M. A multicenter, randomized, vehicle-controlled clinical study to examine the efficacy and safety of MAS063DP (Atopiclair) in the management of mild to moderate atopic dermatitis in adults. J Drugs Dermatol 2006;5:236-244
37. Eberlein B, Eicke C, Reinhardt HW, et al. Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study). J Eur Acad Dermatol Venereol 2008;22:73-82
38. Lambert DM, Vandevoorde S, Jonsson KO, et al. The palmitoylethanolamide family: a new class of anti-inflammatory agents? Curr Med Chem 2002; 9:663-674
39. Madaan A. Epiceram for the treatment of atopic dermatitis. Drugs Today (Barc) 2008;44:751-755
40. Patrizi A, Capitanio B, Neri I, et al. A double-blind, randomized, vehicle-controlled clinical study to evaluate the efficacy and safety of MAS063DP (ATOPICLAIR(TM)) in the management of atopic dermatitis in paediatric patients. Pediatr Allergy Immunol 2008;19:619-625
41. Abramovits W, Perlmutter A. MimyX cream. Skinmed 2006;5:29-30
42. Simpson E, Tofte S, Hanifin J, et al. EpiCeram for the Treatment of Mild-to-Moderate Atopic Dermatitis-A Pilot Study International Investigative Dermatology Meeting, Kyoto, Japan, 2008
43. Ohya Y, Williams H, Steptoe A, et al. Psychosocial factors and adherence to treatment advice in childhood atopic dermatitis. J Invest Dermatol 2001;117:852-857
44. Beattie PE, Lewis-Jones MS. Parental knowledge of topical therapies in the treatment of childhood atopic dermatitis. Clin Exp Dermatol 2003;28:549-553
45. Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol 2000;142:931-936
46. Cork MJ, Britton J, Butler L, et al. Comparison of parent knowledge, therapy utilization and severity of atopic eczema before and after explanation and demonstration of topical therapies by a specialist dermatology nurse. Br J Dermatol 2003;149:582-589
47. Feldman SR, Camacho FT, Krejci-Manwaring J, et al Adherence to topical therapy increases around the time of office visits. J Am Acad Dermatol 2007;57:81-83